Why the study?
Onco-hypertension is an emerging field, but the effect of anti-cancer agents on blood pressure requires detailing across drug classes.
What is the effect of various anti-cancer agents on blood pressure and what are the underlying pathophysiological mechanisms?
What is the effect of various anti-cancer agents on blood pressure and what are the underlying pathophysiological mechanisms?
This review highlights the mechanisms of hypertension induced by anti-cancer agents and emphasizes the need for future studies to determine optimal management strategies in the emerging field of onco-hypertension.
Onco-hypertension is an emerging field investigating the relationship between hypertension and cancer. This paper details one part of this relationship—the effect of anti-cancer agents on blood pressure. We review the evidence linking targeted therapies, immunotherapy, traditional chemotherapies, and hormonal agents with hypertension. Proposed pathophysiological mechanisms vary by drug but include endothelial dysfunction, altered sodium homeostasis, and nephrotoxicity. Despite growing interest in the field, there is a paucity of data on the clinical significance of treatment related hypertension and the optimal management strategy. This should be a focus of future studies.
No takes yet. Share an insight, caveat, or question.
Ruf et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: